13 hrs ago
The Cooper Companies Reaches New 52-Week High Following Analyst Upgrade
The Cooper Companies 's share price reached a new 52-week high during trading on Thursday after Raymond James raised their price target on the stock from $160.00 to $175.00, AnalystRatings.NET reports.
The Cooper Companies Receives Neutral Rating from Zacks
's stock had its "neutral" rating reissued by Zacks in a research note issued on Wednesday.
The Cooper Companies Sets New 12-Month High on Analyst Upgrade
The Cooper Companies shares reached a new 52-week high on Monday after Stifel Nicolaus raised their price target on the stock from $150.00 to $180.00, Analyst RN reports.
The Cooper Companies Price Target Raised to $180.00 at Stifel Nicolaus
The firm currently has a "buy" rating on the stock. Stifel Nicolaus' target price would suggest a potential upside of 11.50% from the stock's previous close.
CooperVision Completes Acquisition of Sauflon, Expanding Its One-Day CL Options
PLEASONTON, Calif.-The Cooper Companies, Inc. , parent of CooperVision , has completed the acquisition of Sauflon Pharmaceuticals Ltd., manufacturer and distributor of soft contact lenses and solutions.
The Cooper Companies Completes Acquisition of Sauflon Pharmaceuticals ...
About is a global medical device company publicly traded on the NYSE Euronext . Cooper is dedicated to being A Quality of Life Company with a focus on delivering shareholder value.
Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014
Metachromatic Leukodystrophy Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, "Metachromatic Leukodystrophy Global Clinical Trials Review, H2, 2014" provides data on the Metachromatic Leukodystrophy clinical trial scenario.